How Women Can Improve Their Fertility & Hormone Health | Dr. Natalie Crawford

Episode Summary

Executive Summary: Dr. Natalie Crawford and Andrew Huberman discuss fertility as a marker of overall health, emphasizing that women should proactively assess ovarian reserve, ovulation, and inflammation rather than waiting for infertility. The episode argues for AMH testing, cycle/ovulation tracking, early evaluation of red flags, and lifestyle/supplement strategies to improve reproductive and hormone health across the lifespan.

Main Topics: Fertility as a general health marker (Priority: 5/5): Fertility is framed not just as the ability to conceive, but as a readout of hormonal, metabolic, cellular, and inflammatory health that can predict long-term wellbeing and aging. AMH testing and ovarian reserve (Priority: 5/5): Crawford strongly advocates AMH testing for anyone who may want children, arguing it helps estimate egg quantity, informs planning, and can reveal issues earlier than waiting for infertility. Cycle tracking, ovulation, and perimenopause (Priority: 5/5): The discussion explains why regular periods are not enough; tracking ovulation and cycle phases can reveal luteal phase defects or early ovulatory dysfunction, even before obvious cycle changes. Lifestyle, inflammation, and egg/sperm quality (Priority: 4/5): Sleep, stress, exercise, muscle mass, nutrition, toxin avoidance, and supplements are presented as modifiable factors that can reduce inflammation and improve reproductive outcomes. Assisted reproduction, egg freezing, and access (Priority: 4/5): The episode covers misconceptions about egg freezing, the ethics of IVF, insurance coverage, and the idea that patients should have access to fertility preservation without being forced to fail first. Medications, substances, and endocrine disruptors (Priority: 4/5): They discuss how NSAIDs, cannabis, nicotine, alcohol, endocrine disruptors, and some supplements can impair ovulation, sperm quality, pregnancy outcomes, or lab accuracy. Personal experience, stigma, and reform in fertility care (Priority: 3/5): Crawford shares her own pregnancy-loss history and uses it to argue for more patient-centered, preventive, less dismissive fertility medicine.

Key Arguments: Fertility reflects more than reproduction; it signals underlying hormonal, metabolic, and inflammatory health. Women should not wait until formal infertility to get evaluated; early testing can change decisions and timelines. AMH is useful for estimating ovarian reserve, even though it does not measure egg quality or guarantee pregnancy. Regular bleeding does not always mean normal ovulation; tracking ovulation provides more sensitive information. Many fertility-relevant problems are modifiable through sleep, muscle building, nutrition, stress management, and toxin reduction. Infertility and pregnancy loss should be evaluated earlier than current norms, which often require patients to fail first. Egg freezing does not reduce ovarian reserve; it uses eggs that would otherwise be lost that cycle. Cannabis and nicotine are strongly associated with worse sperm, egg, embryo, and pregnancy outcomes and should be avoided when trying to conceive. Some supplements and interventions (e.g., CoQ10, omega-3s, melatonin in select cases) may support fertility, but should be targeted rather than universal. Patients deserve data and choice; paternalistic withholding of fertility information is outdated and harmful.

Data Points: AMH test cost: $79 - Crawford says AMH testing is relatively inexpensive and should be accessible out of pocket. Natural fertility at age 30: ~20% chance per month - Quoted as fecundability in the Time to Conceive data for a 30-year-old trying to conceive. Natural fertility at age 35–36: 11–12% chance per month - Age-related decline in fecundability from cohort data. Natural fertility at age 38: 5% chance per month - Quoted monthly conception probability in older age range. Natural fertility at age 40+: 3% chance per month - Monthly conception probability after age 40. Pregnancy in prior-live-birth group: 18–20% per month up to age 37 - Women who previously conceived with the same partner had higher monthly fecundability until late 30s. Infertility diagnosis timing: 12 months of trying; 6 months if age 35+ - They criticize waiting this long before evaluation in current practice. People conceiving in first 6 months: 72% - Most pregnancies occur early in the trying period. People conceiving in next 6 months: 13% - A much smaller share conceive after the first six months. Egg count at 5 months gestation: 6–7 million - Approximate peak egg number before birth. Egg count at birth: 1–2 million - Egg reserve declines before birth. Egg count at first period: ~500,000 - Further decline by menarche. Hormone replacement timing: Can start in perimenopause - Crawford argues women should not have to wait for 12 months without periods to be offered therapy. Poor sleep and infertility: Double the rate of infertility - Subjectively poor sleep is linked with significantly higher infertility rates. Melatonin dose discussed: 1–3 mg - Suggested low-dose melatonin before bed in select patients. Sperm lifespan: ~90 days - Used to explain why lifestyle changes take time to affect sperm quality. Egg vulnerability window: ~60 days before conception - Crawford describes a preconception window when egg quality is most influenced by environment. NSAID effect on ovulation: Can prevent follicle rupture - Ibuprofen/Advil/Aleve around ovulation may block release of the egg. Birth control pill half-life: 28 hours - Used to explain why ovulation typically resumes quickly after stopping the pill. Progesterone IUD fertility effect: Can take ~6 months after removal - Crawford recommends allowing time for endometrial recovery before trying to conceive. Depo-Provera impact: Can prevent ovulation for 18 months from one dose - Why it is discouraged if pregnancy may be desired within two years. Egg freezing cycle outcomes: 90% freeze-thaw survival; 75% fertilization; 50% to implantation stage; 65% live birth from genetically normal embryo - Crawford describes attrition at each step in IVF/embryo creation. Cannabis and female egg retrieval: 25% fewer eggs retrieved - Prior-year cannabis use in women is said to reduce retrieval yield. Cannabis and fertilization: 28% decrease - Cannabis use associated with lower fertilization rates. Cannabis and miscarriage: Increased miscarriage rates - Mentioned for women and in male-partner exposure contexts. Biotin interference threshold: ≥300 micrograms for 7 days - Can distort hormone lab assays such as estradiol, progesterone, hCG, TSH, and testosterone. GLP-1 use in fertility context: Low-dose, 3 months in select inflammatory cases - Used experimentally for endometriosis/probable endo to reduce inflammation before IVF.

Pivotal Quotes: "Everybody should get an AMH test. I think it's a very important marker." — Dr. Natalie Crawford: Her central argument for proactive fertility assessment in anyone who may want children. "Fertility is a health marker." — Dr. Natalie Crawford: Defines the episode’s core framework: fertility as a window into overall health, not only conception. "I do not view myself as the gatekeeper of information about your body." — Dr. Natalie Crawford: Her stance against withholding fertility testing and data from patients.

Implications: Listeners are urged to treat fertility as preventive health, not a crisis to address after failure. The episode pushes earlier testing, informed choice, and lifestyle action, while suggesting fertility care should become more proactive, personalized, and less paternalistic.